Allergy Asthma Immunol Res.  2019 Nov;11(6):760-762. 10.4168/aair.2019.11.6.760.

Risk of Pneumonia Associated With the Use of Inhaled Corticosteroids in Asthma

• Kim SH

• KMID: 2459181
• DOI: http://doi.org/10.4168/aair.2019.11.6.760

Abstract

No abstract available.

MeSH Terms

Adrenal Cortex Hormones*
Asthma*
Pneumonia*
Adrenal Cortex Hormones

Reference

1. CONTROLLED trial of effects of cortisone acetate in status asthmaticus; report to the Medical Research Council by the subcommittee on clinical trials in asthma. Lancet. 1956; 271:803–806.

2. Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018; 141:110–116.e7.

3. Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J. 2006; 15:326–331.

4. Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J. 2014; 8:59–65.

5. Restrepo MI, Sibila O, Anzueto A. Pneumonia in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis. 2018; 81:187–197.

6. O'Byrne PM, Pedersen S, Carlsson LG, Radner F, Thorén A, Peterson S, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med. 2011; 183:589–595.

7. Bansal V, Mangi MA, Johnson MM, Festic E. Inhaled corticosteroids and incident pneumonia in patients with asthma: systematic review and meta-analysis. Acta Med Acad. 2015; 44:135–158.

8. Singh G, Schulthess D, Hughes N, Vannieuwenhuyse B, Kalra D. Real world big data for clinical research and drug development. Drug Discov Today. 2018; 23:652–660.

9. Kim MH, Rhee CK, Shim JS, Park SY, Yoo KH, Kim BY, et al. Inhaled corticosteroids in asthma and the risk of pneumonia. Allergy Asthma Immunol Res. 2019; 11:795–805.

10. Iannella H, Luna C, Waterer G. Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated review. Ther Adv Respir Dis. 2016; 10:235–255.

11. Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018; 378:1877–1887.

12. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018; 378:1865–1876.

13. Janson C, Larsson K, Lisspers KH, Ställberg B, Stratelis G, Goike H, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β₂ agonist: observational matched cohort study (PATHOS). BMJ. 2013; 346:f3306.

14. Park HS, Yoon D, Lee HY, Ban GY, Wan Yau Ming S, Jie JL, et al. Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA. Respirology. Forthcoming. 2019.

15. Harpaz R, DuMochel W, Shah NH. Big data and adverse drug reaction detection. Clin Pharmacol Ther. 2016; 99:268–270.